ICON Public (NASDAQ:ICLR) Posts Earnings Results, Beats Expectations By $0.02 EPS

ICON Public (NASDAQ:ICLR - Get Free Report) announced its earnings results on Wednesday. The medical research company reported $3.19 EPS for the quarter, beating the consensus estimate of $3.17 by $0.02, Briefing.com reports. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. The business had revenue of $2 billion for the quarter, compared to analysts' expectations of $2.03 billion. During the same period in the prior year, the business posted $3.47 earnings per share. The firm's revenue was down 4.3% on a year-over-year basis. ICON Public updated its FY 2025 guidance to 12.750-14.250 EPS.

ICON Public Stock Up 0.0 %

NASDAQ:ICLR traded up $0.06 on Monday, hitting $143.02. The stock had a trading volume of 1,400,279 shares, compared to its average volume of 980,627. ICON Public has a 1 year low of $133.28 and a 1 year high of $347.72. The firm's fifty day simple moving average is $165.03 and its two-hundred day simple moving average is $194.75. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26. The stock has a market cap of $11.55 billion, a P/E ratio of 15.01, a price-to-earnings-growth ratio of 1.86 and a beta of 1.23.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ICLR. Citigroup lowered their price objective on ICON Public from $290.00 to $215.00 and set a "buy" rating for the company in a research report on Monday, April 7th. Barclays reduced their price objective on shares of ICON Public from $165.00 to $155.00 and set an "equal weight" rating for the company in a research report on Friday. Robert W. Baird dropped their target price on shares of ICON Public from $192.00 to $160.00 and set a "neutral" rating on the stock in a research report on Friday. JPMorgan Chase & Co. lowered shares of ICON Public from an "overweight" rating to a "neutral" rating and cut their target price for the stock from $265.00 to $150.00 in a research note on Tuesday, April 29th. Finally, Mizuho decreased their price target on shares of ICON Public from $238.00 to $200.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $215.33.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.